Home Metabolism Phospholipase (e.g. PLA) inhibitor Halobetasol Propionate

Halobetasol Propionate

Catalog No.S4089 Synonyms: BMY-30056, CGP-14458

For research use only.

Halobetasol Propionate (BMY-30056, CGP-14458) is an anti-inflammatory and a dermatologic agent commonly used to treat psoriasis. Halobetasol propionate is thought to act by the induction of phospholipase A2 (PLA2) inhibitory proteins.

Halobetasol Propionate Chemical Structure

CAS No. 66852-54-8

Purity & Quality Control

Choose Selective Phospholipase (e.g. PLA) Inhibitors

Related Compound Libraries

Other Phospholipase (e.g. PLA) Products

Download Inhibitor Catalog

Download Inhibitor Catalog
Phospholipase (e.g. PLA) Signaling Pathways

Phospholipase (e.g. PLA) Signaling Pathway Map

Biological Activity

Description Halobetasol Propionate (BMY-30056, CGP-14458) is an anti-inflammatory and a dermatologic agent commonly used to treat psoriasis. Halobetasol propionate is thought to act by the induction of phospholipase A2 (PLA2) inhibitory proteins.
Targets
PLA2 [1]
()
In vitro

Halobetasol propionate is thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. The initial interaction, however, is due to the drug binding to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes.[1]

Protocol (from reference)

Solubility (25°C)

In vitro

 DMSO 97 mg/mL
(200.01 mM)
Ethanol 38 mg/mL
(78.35 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 484.96
Formula

C25H31ClF2O5
CAS No. 66852-54-8
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCC(=O)OC1(C(CC2C1(CC(C3(C2CC(C4=CC(=O)C=CC43C)F)F)O)C)C)C(=O)CCl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03988439 Recruiting Drug: IDP-118 Lotion Psoriasis Bausch Health Americas Inc. March 24 2021 Phase 4
NCT03987763 Recruiting Drug: IDP-122 Lotion Psoriasis Bausch Health Americas Inc. October 22 2019 Phase 4

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Halobetasol Propionate | Halobetasol Propionate ic50 | Halobetasol Propionate price | Halobetasol Propionate cost | Halobetasol Propionate solubility dmso | Halobetasol Propionate purchase | Halobetasol Propionate manufacturer | Halobetasol Propionate research buy | Halobetasol Propionate order | Halobetasol Propionate mouse | Halobetasol Propionate chemical structure | Halobetasol Propionate mw | Halobetasol Propionate molecular weight | Halobetasol Propionate datasheet | Halobetasol Propionate supplier | Halobetasol Propionate in vitro | Halobetasol Propionate cell line | Halobetasol Propionate concentration | Halobetasol Propionate nmr